ArticleFrontiers in immunology2026
Machine learning quantifies immuno-virological interactions: a TRIPOD+AI compliant prediction model for HIV-1 salvage therapy outcomes.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The management of multidrug-resistant HIV-1 in patients experiencing virologic failure remains a critical clinical challenge. Traditional linear scoring systems often fail to adequately capture the complex evolutionary dynamics between the virus, host immunity, and antiretroviral regimens. This study aims to construct and validate a prediction model in line with the TRIPOD+AI statement to quantify the multidimensional, nonlinear interactions among "virus-host-drug" and to guide individualized clinical salvage therapy. Methods: This retrospective cohort study integrated de-identified data from 18 clinical trials in the Stanford HIV Drug Resistance Database (n = 6,844). Seven machine learning algorithms were compared with traditional models. Model evaluation metrics included area under the receiver operating characteristic curve (AUC), Brier score, and calibration curves. TreeSHAP quantified feature contributions and interactions. Ablation studies (DeLong's test) evaluated the incremental predictive value of integrating virological, immunological, and treatment history domains. The algorithmic fairness of the model across populations with different immune statuses and viral loads was evaluated through subgroup analysis, and the Effective Sample Size (ESS) was introduced to assess individual prediction uncertainty. Results: The XGBoost model best predicted 24-week virologic suppression (AUC: 0.887), significantly outperforming the baseline model (AUC: 0.816) with excellent calibration (Brier score: 0.096). Ablation studies confirmed that the integrated model significantly outperformed partial models restricted to single feature domains (all Conclusion: The developed XGBoost model overcomes the limitations of traditional linear scoring and achieves precise prediction of HIV salvage therapy outcomes by quantifying immune modulatory effects and therapeutic exhaustion markers. This model acts as a clinical safeguard to identify ineffective treatments while maintaining algorithmic fairness across patient severities. The developed web-based calculator and risk stratification system help clinicians optimize resource allocation and advance novel drug use in complex resistance scenarios, promoting evidence-based HIV precision medicine practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.